Fig. 5
From: Tumor mutational burden is associated with poor outcomes in diffuse glioma
Pan-cancer targeted sequencing-based TMB cannot predict prognosis in glioma. a Correlation of TMB calculated on the basis of exome sequencing and targeted genes. The list of genes is from the FDA-approved targeted next generation sequencing panel (MSK-IMPACT). Spearman’s r value and significance were calculated. b AUC analysis with TMB calculated using the MSK-IMPACT panel. c Survival analysis was performed with the indicated cut-off value